Affinity Asset Advisors’s AstraZeneca AZN Stock Holding History

Affinity Asset Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30,000	Closed	-$4.04M	–	102
2023 Q4	$4.04M	Hold	30,000	–	–	0.74%	38
2023 Q3	$4.06M	Hold	30,000	–	–	1.14%	30
2023 Q2	$4.29M	Hold	30,000	–	–	1.5%	22
2023 Q1	$4.16M	Hold	30,000	–	–	1.37%	25
2022 Q4	$4.07M	Sell	30,000 -45,000	-60%	-$5.64M	1.6%	22
2022 Q3	$8.23M	Buy	75,000 +32,500	+76%	+$4.12M	2.3%	14
2022 Q2	$5.62M	Sell	42,500 -37,500	-47%	-$4.92M	2.37%	15
2022 Q1	$10.6M	Buy	+80,000	New	+$9.59M	1.7%	10

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Affinity Asset Advisors's AZN Position: Q1 2024 in Review

Affinity Asset Advisors sold out of AstraZeneca (AZN) in Q1 2024, closing a stake of 30,000 shares — an estimated $4.04M sold.

Affinity Asset Advisors first reported a position in AZN in Q1 2022 and held it in 8 quarters. The position peaked at $10.6M in Q1 2022. 1,141 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

Affinity Asset Advisors reported no remaining AstraZeneca position as of Q1 2024 after selling out during the quarter.
Affinity Asset Advisors sold 30,000 AstraZeneca shares in Q1 2024, an estimated $4.04M.
Affinity Asset Advisors first reported a position in AstraZeneca in Q1 2022 and held it in 8 quarters.
Affinity Asset Advisors's AstraZeneca position peaked at $10.6M in Q1 2022.
1,141 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Affinity Asset Advisors's 13F filing for Q1 2024, filed 14 May 2024.